Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) shares traded down 6% on Thursday . The company traded as low as $9.67 and last traded at $9.65. 60,674 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 269,752 shares. The stock had previously closed at $10.26.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on TYRA shares. Piper Sandler initiated coverage on Tyra Biosciences in a research note on Wednesday, May 21st. They issued an "overweight" rating and a $33.00 target price for the company. Wedbush reiterated an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, March 28th. Finally, HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, March 31st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tyra Biosciences presently has an average rating of "Buy" and an average price target of $30.83.
Check Out Our Latest Report on TYRA
Tyra Biosciences Stock Up 3.7%
The business's fifty day moving average is $9.31 and its 200-day moving average is $12.14. The company has a market cap of $560.10 million, a PE ratio of -6.55 and a beta of 1.07.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. Analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new position in Tyra Biosciences in the 4th quarter worth about $31,000. US Bancorp DE acquired a new stake in Tyra Biosciences in the fourth quarter valued at approximately $50,000. BNP Paribas Financial Markets acquired a new stake in shares of Tyra Biosciences in the 4th quarter worth $60,000. Aquatic Capital Management LLC acquired a new stake in Tyra Biosciences in the fourth quarter worth about $64,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Tyra Biosciences during the 1st quarter worth approximately $84,000. Institutional investors own 84.14% of the company's stock.
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Featured Stories
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
